Tag: Sandoz

Sandoz Voluntary Recalls Losartan Potassium and Ezetimibe Bottles

A voluntary recall for Losartan Potassium and Ezetimibe prescription drug bottles has been announced in the US due to the packaging not being child-resistant. About 636,000 units of Ezetimibe 10mg ...

Sandoz Struck Deal with Polpharma Biologics to Market Biosimilar Drug Tysabri

Novartis’ biosimilars and generics arm Sandoz has struck a deal with Polpharma Biologics to market a proposed biosimilar of Biogen’s multiple sclerosis drug Tysabri (natalizumab). Tysabri’s main US...

Sandoz Entered into Global Commercialization Agreement with Polpharma Biologics

Sandoz, a Novartis division and a global leader in biosimilars, announced that it has entered into a global commercialization agreement for a proposed natalizumab biosimilar. The medicine is in Phase ...

Sandoz Announced Launch of Generic Oncology Medicine Gefitinib in 13 EU Countries

Sandoz announced the launch of the generic oncology medicine gefitinib indicated for adult patients with locally advanced or metastatic non-small cell lung cancer with activating mutations of EGFR-TK,...

Sandoz Agreed with Kit Check to Automate Restocking of Sandoz Products in the U.S.

Sandoz Inc, a Novartis division, announced that it has entered into an agreement with Kit Check, Inc., a leader in automated medication management solutions for hospitals, to automate the restocking o...

Sandoz Announced Data from Phase III ADMYRA Trial of Bosimilar Hyrimoz

Sandoz, a Novartis division and a global leader in biosimilars, announced data from the Phase III ADMYRA trial demonstrating that the efficacy and safety of biosimilar Hyrimoz® (adalimumab) matches th...

Sandoz to Commercialize Inovaitive Med in Key EU Markets

Sandoz today announces that it has signed an agreement with Shionogi & Co Ltd for commercialization of Rizmoic® (naldemedine) in the key European markets of Germany, the UK and the Netherlands, pl...

CEO of Sandoz Steps Dows

Novartis announced today that Richard Francis will be stepping down as CEO of Sandoz, a Novartis division, and as a member of the Executive Committee of Novartis on March 31, 2019. Francesco Balestrie...

First FDA-Cleared PDT for Opioid Use Disorder

Sandoz Inc., a division of Novartis, and Pear Therapeutics, Inc., the leader in prescription digital therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted clearanc...

Novartis and Gan & Lee to Produce Insulin Biosimilars

Swiss drugmaker Novartis aims to become a big player in supplying insulin to swelling numbers of diabetics, signing a deal with China’s Gan & Lee on versions of three blockbuster brands as the U.S...

Sandoz and Pear Therapeutics launched the first digital therapeutic

digital drug
Sandoz, a Novartis division, and Pear Therapeutics, announced the commercial launch of reSET, the first FDA-authorized prescription digital therapeutic, for patients with Substance Use Disorder.

Novartis sells parts of its Sandoz US portfolio to Aurobindo Pharma

Novartis announced it has agreed to sell selected portions of its Sandoz US portfolio, specifically the Sandoz US dermatology business and generic US oral solids portfolio, to Aurobindo Pharma.

Sandoz obtained EC approval for infliximab biosimilar

Sandoz, a Novartis division and the global leader in biosimilars, announced that the European Commission (EC) has approved Zessly (infliximab) for use in Europe.

Sandoz and Pear Therapeutics will jointly develop digital therapeutics

digital drug
Sandoz, a Novartis division and global leader in generic pharmaceuticals and biosimilars, entered into a collaboration with Pear Therapeutics to commercialize and continued development of novel prescription digital therapeutics.

Tilray set up a strategic alliance with a leading Canadian pharma company

medicinal cannabis
Tilray, a licensed producer of medical cannabis, signed a binding letter of intent to be the collaborator of a major pharma company to accelerate innovation and increase availability of high quality medical cannabis products.

Sandoz and Biocon partnered to develop multiple biosimilars

Sandoz, a Novartis division, announced a global partnership with Asia's premier biopharmaceuticals company, Biocon, to develop, manufacture and commercialize multiple biosimilars